secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ceribell, Inc. (CBLL)
CIK:        0001861107
Form:       8-K
Filed at:   2026-05-11T20:16:47+00:00
Accession:  0001193125-26-216821
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ceribell Q1 revenue $26.5M (+29% YoY); raises FY2026 guidance to $112-116M
--------------------------------------------------------------------------

- Revenue $26.5M, up 29% YoY; product $20.2M, subscription $6.3M, both +29%.
- Net loss $19.7M ($0.52/sh) vs $12.8M ($0.36) YoY; adj. EBITDA loss $11.2M.
- Launched neonate/pediatric EEG products; 680 active accounts at quarter end.
- CMS proposed rule for NTAP reimbursement for delirium monitoring; final rule Aug 2026.
- FY2026 revenue guidance raised to $112-116M (26-30% growth); cash $141.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861107/000119312526216821/0001193125-26-216821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861107/000119312526216821/cbll-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer